The analyzed compounds that inhibit CA II can be used for testing new treatment modalities in cases of glaucoma, neoplasms, and neurodegenerative diseases, diseases in which a great improvement was observed following the inhibition of the CA enzyme [105]. Here, CA2 is linked to glaucoma.